Jeff Yass’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jeff Yass’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.25M	Sell	321,000 -280,600	-47%	-$5.09M	﹤0.01%	4202
2026 Q1	$11.2M	Buy	601,600 +112,500	+23%	+$1.86M	﹤0.01%	2938
2025 Q4	$6.45M	Sell	489,100 -62,400	-11%	-$736K	﹤0.01%	3640
2025 Q3	$3.95M	Buy	551,500 +420,500	+321%	+$21.9M	﹤0.01%	4492
2025 Q2	$6.18M	Buy	131,000 +64,200	+96%	+$2.62M	﹤0.01%	3602
2025 Q1	$2.61M	Buy	66,800 +18,200	+37%	+$784K	﹤0.01%	4955
2024 Q4	$2.63M	Buy	48,600 +30,100	+163%	+$1.54M	﹤0.01%	4712
2024 Q3	$933K	Sell	18,500 -32,200	-64%	-$1.51M	﹤0.01%	6947
2024 Q2	$2.23M	Buy	50,700 +8,300	+20%	+$352K	﹤0.01%	4889
2024 Q1	$2.13M	Buy	42,400 +10,400	+33%	+$564K	﹤0.01%	5190
2023 Q4	$1.93M	Sell	32,000 -1,000	-3%	-$51.5K	﹤0.01%	5433
2023 Q3	$1.88M	Buy	+33,000	New	+$1.82M	﹤0.01%	5260

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jeff Yass's MLTX Position: Q2 2026 in Review

Jeff Yass reduced its MoonLake Immunotherapeutics (MLTX) stake by 27% in Q2 2026, selling an estimated $1.7M and leaving 247,742 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #4683.

Jeff Yass first reported a position in MLTX in Q3 2023 and has held it in 8 quarters since. The position peaked at $12.9M in Q4 2023. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Jeff Yass held 247,742 shares of MoonLake Immunotherapeutics worth $4.82M as of Q2 2026.
Jeff Yass sold 93,682 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.7M.
MoonLake Immunotherapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4683 holding.
Jeff Yass first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 8 quarters since.
Jeff Yass's MoonLake Immunotherapeutics position peaked at $12.9M in Q4 2023.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.